• Species Reactivity
  Mouse
• Specificity
  Detects mouse TNF RI/TNFRSF1A in direct ELISAs and Western blots. In direct ELISAs and Western blots (non-reducing conditions), less than 5% cross-reactivity with recombinant human TNF RI is observed.
• Source
  Polyclonal Goat IgG
• Purification
  Antigen Affinity-purified
• Immunogen
  E. coli-derived recombinant mouse TNF RI
  Ile22-Ala212
  Accession # P25118
• Formulation
  Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
• Endotoxin Level
  <0.10 eu="" per="" 1="" μg="" of="" the="" antibody="" by="" the="" lal="">
• Label
  Unconjugated

• Western Blot
  0.2 µg/mL
  See below
• Flow Cytometry
  2.5 µg/10⁶ cells
  See below
• Immunohistochemistry
  5-15 µg/mL
  Perfusion fixed frozen sections of mouse intestine
• Agonist Activity
  Measured in a cytotoxicity assay using L-929 mouse fibrosarcoma cells in the presence of the metabolic inhibitor actinomycin D.
  The ED₅₀ for this effect is typically 0.05-0.15 μg/mL.
• CyTOF-ready
  Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.

• Reconstitution
  Reconstitute at 0.2 mg/mL in sterile PBS.
• Shipping
  The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
• Stability & Storage
  Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

• References:
  1. Pfeffer, K. (2003) Cytokine Growth Factor Rev. 14:185.
  2. Hehlgans, T. and K. Pfeffer (2005) Immunology 115:1.
  3. Peschon, J.J. et al. (1998) J. Immunol. 160:943.
  4. Banner, D.W et al. (1993) Cell 73:431.
  5. Medvedev, A.E. et al. (1996) J. Biol. Chem. 271:9778.
  6. Chan, F.K. et al. (2000) Science 288:2351.
  7. Legler, D.F. et al. (2003) Immunity 18:655.
  8. Tellier, E. et al. (2006) Exp. Cell Res. 312:3969.
  9. Xanthoulea, S. et al. (2004) J. Exp. Med. 200:367.
  10. Jin, L. et al. (2000) J. Immunol. 165:5153.
  11. Gomez, M.I. et al. (2006) J. Biol. Chem. 281:20190.
  12. Islam, A. et al. (2006) J. Biol. Chem. 281:6860.
  13. Garton, K.J. et al. (2006) J. Leukoc. Biol. 79:1105.
  14. McDermott, M.F. et al. (1999) Cell 97:133.
  15. Schneider-Brachert, W. et al. (2004) Immunity 21:415.
  16. Lewis, M. et al. (1991) Proc. Natl. Acad. Sci. USA 88:2830.
• Long Name:
  Tumor Necrosis Factor Receptor I
• Entrez Gene IDs:
  7132 (Human); 21937 (Mouse); 25625 (Rat)
• Alternate Names:
  CD120a antigen; CD120a; FPF; p55; p55-R; p60; TNF RI; TNFARMGC19588; TNF-R; TNF-R1; TNFR1TBP1; TNFR55; TNF-R55; TNFR60; TNFRI; TNF-RI; TNF-R-I; TNFR-I; TNFRSF1A; tumor necrosis factor binding protein 1; Tumor necrosis factor receptor 1; tumor necrosis factor receptor 1A isoform beta; tumor necrosis factor receptor superfamily member 1A; tumor necrosis factor receptor superfamily, member 1A; tumor necrosis factor receptor type 1; Tumor necrosis factor receptor type I; tumor necrosis factor-alpha receptor

Background:

TNF receptor 1 (TNF RI; also called TNF R‑p55/p60, TNFRSF1A and CD120a) is a type I transmembrane protein that belongs to the TNF receptor superfamily (1, 2). TNF RI is widely expressed and is present on the cell surface as a trimer of 55 kDa subunits. It serves as a receptor for both TNF‑ alphaand TNF‑ beta /lymphotoxin. Each subunit contains four TNF‑ alphatrimer‑binding cysteine‑rich domains (CRD) in its extracellular domain (ECD) (1‑6). TNF‑ alphabinding to TNF R1 induces the sequestration of TNFRI in lipid rafts, where it activates NF kappa B and is cleaved by ADAM‑17/TACE (7, 8). Release of the 28‑34 kDa TNF RI ECD occurs constitutively, and in response to products of pathogens such as LPS, CpG DNA or S. aureus protein A (1, 7‑12). Full‑length TNF RI may also be released in exosome‑like vesicles (12). Such release helps to resolve inflammatory reactions as it down‑regulates cell surface TNF RI and provides soluble TNF RI to bind TNF‑ alpha(6, 13, 14). Exclusion from lipid rafts causes endocytosis of TNF RI complexes and induces apoptosis (7, 15). Although there is a second receptor for TNF‑ alpha(TNF R2), TNF RI is thought to mediate most of the cellular effects of TNF‑ alpha(3). TNF R1 is essential for proper development of lymph node germinal centers and Peyer’s patches, and for combating intracellular pathogens such as Listeria monocytogenes (1‑3). Mouse TNF RI is a 454 amino acid (aa) protein that contains a 21 aa signal sequence and a 191 aa ECD with a PLAD domain (6). This mediates constitutive trimer formation. The PLAD domain is followed by four CRDs, a 23 aa transmembrane domain, and a 219 aa cytoplasmic sequence that contains a neutral sphingomyelinase activation domain and a death domain (16). The ECD of mouse TNF RI shows 67%, 70%, 64%, 70% and 88% aa identity with canine, feline, procine, human and rat TNF RI, respectively; and it shows 23% aa identity with the ECD of TNF RII.

      R&D Systems位于美国的明尼苏达州，一直致力于生物制品的开发与生产。公司成立之初主要生产用于医院及临床应用的血控品。1997年，公司推出第一个产品--富血小板血浆质控品；1981年，公司成为全球第二家生产含血小板全血控品的供应商。40多年的发展中，R&D Systems仍持续开发各种血控品产品。

  1985年，作为公司推出的第一个科研试剂产品，也是全球第一家将该产品进行商业化生产的产品，R&D Systems成功上市了TGF-beta1蛋白。作为胞外信号分子，TGF-beta1蛋白在多种细胞中进行表达，并作为胞外信号分子参与免疫功能，细胞增殖和细胞分化等生物学过程。该产品推出后，公司陆续从生物材料中纯化了几种细胞因子产品并推向市场。

  天然蛋白类产品的成功推广，加速了R&D Systems在细胞因子市场的开拓。公司于1985年形成Growth Factor事业部（现Biotechnology事业部）。Biotechnology事业部的目标是生产和营销重组人细胞因子。与天然来源提取蛋白相比较，DNA重组技术生产的蛋白产品其成本更低，产量更高，完全摆脱原料的限制。1989年，Biotechnology事业部开始开发抗细胞因子的单克隆和多克隆抗体，并于1990年开发了第一个ELISA试剂盒。

  2014年2月10日，R&D Systems的母公司宣布命名为Bio-Techne. Bio-Techne旗下包括R&D Systems, Novus Biologicals, BiosPacific, Tocris Bioscience, Boston Biochem和Bionostics。